Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Chemotherapy in Adjuvant Pleural Mesothelioma
NCT04177953Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Feb 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in malignant pleural mesothelioma (MPM), sponsored by Institut für Klinische Krebsforschung. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04177953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177953.